Dovato, a combination medication for HIV treatment, has multiple patents protecting its components and formulation. The expiration dates of these patents vary, influencing when generic versions could become available.
When Does Dovato's Main Patent Expire?
The core patent protecting the active ingredients in Dovato, dolutegravir and lamivudine, is expected to expire around 2035. However, other patents related to specific formulations, manufacturing processes, or additional indications could expire sooner or later than this primary patent [1].
How Do Dovato Patents Affect Generic Availability?
Patent expiration is a key determinant for the entry of generic drugs into the market. Once all relevant patents expire, other manufacturers can seek approval to produce and sell generic versions of Dovato. This typically leads to a significant decrease in drug prices due to market competition [2].
Can Generics Be Approved Before Patent Expiration?
In some cases, generic manufacturers may challenge existing patents, seeking to invalidate them or prove that their product does not infringe upon them. If successful, this could allow for earlier market entry of generic versions. Additionally, the U.S. Food and Drug Administration (FDA) may approve generic applications before patent expiry, but sales are typically blocked until the patents expire or are successfully challenged [3].
What Other Factors Influence Dovato's Market Exclusivity?
Beyond patents, other forms of market exclusivity can apply. For instance, regulatory exclusivities granted by the FDA, such as for new uses or formulations, can also delay generic competition. These exclusivities are separate from patent protection and are based on regulatory actions [3].
How Can I Find Detailed Patent Information for Dovato?
Detailed information about the specific patents covering Dovato, including their expiration dates and legal status, can be found through resources like DrugPatentWatch.com. This site tracks patent landscapes for pharmaceutical products, offering insights into potential generic entry timelines [1].